Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Fibroblast growth factor receptor (FGFR) signaling is implicated in various human cancers.
• Recent FDA approvals highlight the clinical relevance of FGFR inhibitors in biomarker-selected populations.
• Diverse technologies are employed in clinical trials to assess FGFR pathway alterations.

Purpose of the Study:

• To review and compare the advantages and limitations of different technologies used for biomarker detection in FGFR-targeted cancer therapy.
• To discuss the critical role of tissue and disease context in selecting the optimal predictive biomarker.
• To provide insights for the effective application of FGFR inhibitors in clinical practice.

Main Methods:

• Review of existing literature on technologies for FGFR biomarker assessment.
• Comparative analysis of protein (immunohistochemistry), mRNA (RNA in situ hybridization), and DNA alteration detection methods (copy number variations, mutations, gene fusions).
• Discussion of the impact of tissue and disease context on biomarker utility.

Main Results:

• Various technologies offer different strengths and weaknesses for detecting FGFR alterations.
• Protein, mRNA, and DNA-based methods each have unique applications and limitations.
• Tissue and disease context significantly influence the choice and interpretation of biomarkers.

Conclusions:

• Accurate identification of predictive biomarkers is crucial for the success of FGFR-targeted therapies.
• A comprehensive understanding of available technologies and their limitations is essential.
• Integrating tissue and disease context is key to optimizing patient selection for FGFR inhibitors.